Valuation
NVSNovartis AG
StockNYSEZwitserlandHealth careEU retail: available
10/10
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | NVS | Sector median | vs median |
|---|---|---|---|
| P/E | 20,0 | 15,6 · n=8 | 29% above |
| P/B | 6,1 | 2,3 · n=14 | 163% above |
| P/S | — | 3,5 · n=11 | — |
| EV/EBIT | 16,9 | 16,9 · n=7 | near the median |
| Free-cash-flow yield | 6,3% | 5,0% · n=12 | 27% above |
| Dividend yield | 3,25% | 1,67% · n=58 | 94% above |
| Return on equity | 31,0% | 2,5% · n=14 | 1.154% above |
| Return on invested capital | 25,0% | 4,6% · n=11 | 441% above |
| Gross margin | — | 66,3% · n=8 | — |
Value factor: 79 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| Instrument | P/E | P/B | EV/EBIT | Free-cash-flow yield | Dividend yield | Smart Score |
|---|---|---|---|---|---|---|
| SNYSanofi | 11,1 | 1,2 | 15,3 | 8,3% | 6,1% | 7/10 |
| ALCAlcon | 31,8 | 1,4 | 25,2 | 5,6% | 0,6% | 5/10 |
| BNTXBioNTech SE | — | 1,0 | — | 1,4% | 0,0% | —/10 |
| STESTERIS | 26,3 | 2,9 | 19,8 | 4,4% | 0,9% | 7/10 |
| ICLRICON plc | 307,9 | 1,4 | 56,6 | 6,8% | 0,0% | 3/10 |
| CRSPCRISPR Therapeutics AG | — | 2,8 | — | −7,6% | 0,0% | 1/10 |
| ABCLAbCellera Biologics | — | 4,2 | — | −3,2% | 0,0% | 1/10 |
| ZLABZai Lab Ltd | — | 4,2 | — | −5,5% | 0,0% | 1/10 |
| AUPHAurinia Pharmaceuticals | 7,0 | 3,6 | — | — | 0,0% | —/10 |
| NVCRNovoCure Limited | — | 4,8 | — | −1,6% | 0,0% | 2/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 dec 2025 · filed 04 feb 2026
Hier opzeggen · EU-consumenten: 14 dagen bedenktijd bij aankoop.